insights_auto
Hvorfor har 2X1 gått ned? 2,99%?
Gå mer i dybdenchevron_right
2X1:ETR
Abivax SA
81,05 €
arrow_downward
−2,99%(−2,50) 1 D
5. okt., 17:35:32 GMT+2 · EUR
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for 2X1 …
Åpne
83,05 €
Høy
83,05 €
Lav
80,10 €
Markedsverdi
7,08 mrd.
Snittvolum
1,71k
Volum
701,00
52 u høy
137,40 €
52 u lav
60,85 €
EPS
−5,20 €
Antall ansatte
98
Åpne
83,05 €
Høy
83,05 €
Lav
80,10 €
Markedsverdi
7,08 mrd.
Snittvolum
1,71k
Volum
701,00
52 u høy
137,40 €
52 u lav
60,85 €
EPS
−5,20 €
Antall ansatte
98
Nyhetssaker
Fra nettkilder og nyhetspartnere
Invezz
·
for 5 timer siden
Dow Jones: Fire hoveddrivere for amerikanske aksjer denne uken
Invezz
·
for 4 timer siden
Dow faller mens amerikanske aksjer handler blandet ved høye statsobligasjonsrenter og oljepris
sUAS News
·
for 1 time siden
Powerus (Nasdaq: PUSA) Awarded $82 Million Order for Counter-Unmanned Aerial Systems
Fortune
·
for 43 minutter siden
NYSE owner and crypto exchange OKX seek SEC clearance for tokenized U.S. stock trading
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Om Abivax SA
Administrerende direktørMarc de Garidel | Hartmut J. Ehrlich
Ansatte98
Grunnlagt4. des. 2013
Hovedkontor-
Sektor-
Nettstedabivax.com